The market for epilepsy treatment is worth $18 billion, yet today’s anti-epilepsy drugs are ineffective for nearly 40% of patients. With new fields of scientific research, addressing this gap could change the lives of millions.
We sat down with Fiona Nielsen, CEO of Neurolentech, to discuss their groundbreaking work identifying novel drug treatments for people living with autism, epilepsy, and intellectual disability.